Continuity of Care Within a Single Patient Support Program for Patients with Rheumatoid Arthritis Prescribed Second or Later Line Advanced Therapy

[1]  Martin Bergman,et al.  Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis , 2021, Advances in Therapy.

[2]  D. Furst,et al.  Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis , 2021, Rheumatology and Therapy.

[3]  A. Fendrick,et al.  Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit. , 2021, Journal of managed care & specialty pharmacy.

[4]  M. Bonafede,et al.  Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data , 2020, Journal of managed care & specialty pharmacy.

[5]  P. Emery,et al.  Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis , 2020, Arthritis Research & Therapy.

[6]  J. Best,et al.  Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic , 2020, Rheumatology and Therapy.

[7]  D. Collier,et al.  Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate , 2020, Journal of managed care & specialty pharmacy.

[8]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[9]  A. Duhig,et al.  Physicians’ perspectives regarding non-medical switching of prescription medications: Results of an internet e-survey , 2020, PloS one.

[10]  R. Frankel,et al.  Professionalism as the Bedrock of High-Value Care , 2020, Academic medicine : journal of the Association of American Medical Colleges.

[11]  E. Teisberg,et al.  Defining and Implementing Value-Based Health Care: A Strategic Framework , 2019, Academic medicine : journal of the Association of American Medical Colleges.

[12]  G. Nagy,et al.  Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. , 2019, Autoimmunity reviews.

[13]  W. Shrank,et al.  Waste in the US Health Care System: Estimated Costs and Potential for Savings. , 2019, JAMA.

[14]  A. Fendrick,et al.  Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population , 2019, Patient preference and adherence.

[15]  Keith J. Johnson,et al.  Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders , 2019, Clinical Rheumatology.

[16]  N. Boytsov,et al.  Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis , 2019, PharmacoEconomics - Open.

[17]  D. Brixner,et al.  Impact of Online Prescription Management Systems on Biologic Treatment Initiation , 2019, Advances in Therapy.

[18]  A. Fendrick,et al.  Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. , 2019, Journal of managed care & specialty pharmacy.

[19]  N. Maniadakis,et al.  A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences , 2018, Advances in Therapy.

[20]  S. Feldman,et al.  Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review , 2018, Patient preference and adherence.

[21]  A. Fendrick,et al.  Value-Based Insurance Design Improves Medication Adherence Without An Increase In Total Health Care Spending. , 2018, Health affairs.

[22]  M. Bonafede,et al.  Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy. , 2018, American health & drug benefits.

[23]  V. Strand,et al.  Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis , 2018, Journal of managed care & specialty pharmacy.

[24]  E. Peterson,et al.  Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy , 2017, JAMA cardiology.

[25]  S. Shinde,et al.  Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA , 2017, Advances in Therapy.

[26]  A. Fendrick,et al.  Low-Cost, High-Volume Health Services Contribute The Most To Unnecessary Health Spending. , 2017, Health affairs.

[27]  J. Kremer,et al.  Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry , 2017, Rheumatology and Therapy.

[28]  R. Desai,et al.  Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis , 2017, Arthritis Research & Therapy.

[29]  Li Wang,et al.  Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy , 2017, Advances in Therapy.

[30]  A. Araujo,et al.  Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014 , 2017, Rheumatology International.

[31]  J. Curtis,et al.  Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis , 2017, Journal of medical economics.

[32]  P. Ravaud,et al.  Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. , 2016, JAMA.

[33]  R. Gerber,et al.  Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs , 2016, Journal of managed care & specialty pharmacy.

[34]  Raveendhara R. Bannuru,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis care & research.

[35]  J. Gómez-Reino,et al.  Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. , 2015, Rheumatology.

[36]  E. Matteson,et al.  Hospitalization rates and utilization among patients with rheumatoid arthritis: a population-based study from 1987 to 2012 in Olmsted County, Minnesota. , 2015, Mayo Clinic proceedings.

[37]  A. Barton,et al.  Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort , 2014, Rheumatology.

[38]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[39]  E. Moy,et al.  Potentially preventable hospitalizations - United States, 2001-2009. , 2013, MMWR supplements.

[40]  Elizabeth A Stuart,et al.  Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. , 2013, Journal of clinical epidemiology.

[41]  D. Berwick,et al.  Eliminating waste in US health care. , 2012, JAMA.

[42]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[43]  A. Fendrick.  Value-based insurance design for diabetes mellitus: approaches to optimal pharmacoeconomic implementation. , 2010, The American journal of managed care.

[44]  A. Fendrick,et al.  Impact of decreasing copayments on medication adherence within a disease management environment. , 2008, Health affairs.

[45]  C. Marano,et al.  To err is human. Building a safer health system , 2005 .

[46]  W. Katon,et al.  Impact of antidepressant drug adherence on comorbid medication use and resource utilization. , 2005, Archives of internal medicine.

[47]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[48]  P. Weiden,et al.  Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. , 2004, Psychiatric services.